FY2024 EPS Estimate for Cytosorbents Decreased by Analyst

Cytosorbents Co. (NASDAQ:CTSO - Free Report) - HC Wainwright lowered their FY2024 EPS estimates for Cytosorbents in a research report issued on Monday, November 11th. HC Wainwright analyst S. Lee now anticipates that the medical research company will earn ($0.30) per share for the year, down from their previous forecast of ($0.29). HC Wainwright currently has a "Neutral" rating and a $1.00 target price on the stock. The consensus estimate for Cytosorbents' current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for Cytosorbents' Q4 2024 earnings at ($0.07) EPS, Q1 2025 earnings at ($0.06) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.14) EPS and FY2027 earnings at ($0.12) EPS.

A number of other brokerages have also commented on CTSO. StockNews.com began coverage on Cytosorbents in a research report on Sunday. They issued a "hold" rating on the stock. EF Hutton Acquisition Co. I upgraded shares of Cytosorbents to a "strong-buy" rating in a research note on Monday, July 29th.

Cytosorbents Stock Performance

Cytosorbents stock traded up $0.03 during trading hours on Thursday, hitting $0.96. 32,825 shares of the stock traded hands, compared to its average volume of 124,970. The firm's 50 day moving average price is $1.13 and its 200-day moving average price is $1.01. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.71. The stock has a market capitalization of $52.49 million, a price-to-earnings ratio of -2.57 and a beta of 0.56. Cytosorbents has a 1 year low of $0.70 and a 1 year high of $2.15.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The medical research company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.01. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. The firm had revenue of $9.89 million for the quarter, compared to analyst estimates of $9.73 million. During the same period in the previous year, the company earned ($0.14) earnings per share.

Hedge Funds Weigh In On Cytosorbents

Large investors have recently added to or reduced their stakes in the stock. Avenir Corp increased its position in shares of Cytosorbents by 4.0% during the first quarter. Avenir Corp now owns 3,172,696 shares of the medical research company's stock worth $3,014,000 after purchasing an additional 121,294 shares in the last quarter. Sargent Investment Group LLC lifted its stake in shares of Cytosorbents by 13.4% in the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company's stock worth $2,439,000 after buying an additional 192,747 shares in the last quarter. CM Management LLC boosted its position in Cytosorbents by 3.0% during the second quarter. CM Management LLC now owns 850,000 shares of the medical research company's stock worth $598,000 after acquiring an additional 25,000 shares during the last quarter. Finally, Atomi Financial Group Inc. purchased a new stake in Cytosorbents during the 3rd quarter valued at about $51,000. 32.87% of the stock is currently owned by institutional investors and hedge funds.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.